1 August 2019 – Takis awarded with the SME Instrument Phase 1
We are proud to announce that Takis biotech has been awarded with the SME Instrument Phase 1(ot EIC accelerator) for its program on Neo-Antigen cancer vaccine, TK-Neo. The aim of the instrument is to fund disruptive ideas and transform them into concrete innovative solutions with European and global impact. The outcome of a phase 1 project is a feasibility report, including a more elaborated business plan.
The EIC Accelerator (SME Instrument) is a public funding programme that funds risk innovation in small businesses. It funds market-creating innovation in disruptive small businesses that have significant growth potential and global ambitions. The EIC Accelerator (SME Instrument) is part of Horizon 2020 – the EU's 80 billion € funding programme for Research and Innovation for 2014-2020.
Only the most innovative companies get selected. Until now, out of over 50.000 applicants 4500 companies have been funded. This shows how intense the competition is under the programme and demonstrates the high quality of the proposals funded. 25% of the companies funded under the EIC SME Instrument are in the 10% fastest growing companies in Europe according to Venture Radar.
We believe that TK-NEO has all the features for providing new therapies and changing cancer patients’ life!
|This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958|